Tiapamil

Tiapamil
Clinical data
Other names	Dimeditiapramine; Ro 11-1781
Identifiers
	IUPAC name 2-(3,4-Dimethoxyphenyl)-2-(3-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}propyl)-1λ6,3λ6-dithiane-1,1,3,3-tetrone;
CAS Number	57010-31-8 ;
PubChem CID	42107;
ChemSpider	38399 ;
UNII	0ONY823T4J;
CompTox Dashboard (EPA)	DTXSID10205620 ;
ECHA InfoCard	100.054.992
Chemical and physical data
Formula	C26H37NO8S2
Molar mass	555.70 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(CCCC1(S(=O)(=O)CCCS1(=O)=O)C2=CC(=C(C=C2)OC)OC)CCC3=CC(=C(C=C3)OC)OC;

Tiapamil (INN; also known as dimeditiapramine) is a calcium antagonist or calcium channel blocker.^[1]^[2] It is an experimental drug that has never been marketed.^[3]

Tiapamil has been described as an antianginal agent. It exhibits properties of anti-arrhythmic medications. These are medications that are used to treat unusually fast or irregular heartbeats. Examples of arrhytmthic conditions include atrial fibrillation, atrial flutter, and super-ventricular tachycardia.^[4] Upon research, the drug shows promising effects on treatment of these condition. Research seeks to create a treatment with tiapamil in order to mitigate the side effects of the more commonly prescribed calcium antagonist and anti-hypertensive verapamil. The two drugs have similar properties; however, tiapamil appears to treat arrhythmic conditions without many of the hypotensive, negative inotropic, and negative chronotropic side effects. Tiapamil is a calcium channel blocker that acts on the slow calcium channels. It can treat ventricular arrhythmias to a higher degree than traditional calcium antagonists.^{[medical citation needed]}

References

^ Cocco G, Strozzi C, Chu D (June 1979). "Human electropharmacology of the calcium antagonist dimeditiapramine (Ro 11-1781) in coronary patients". Clinical Cardiology. 2 (3): 212–216. doi:10.1002/clc.4960020307. PMID 509799. S2CID 24609271.
^ Nowak FG, Cocco G, Chu D, Gasser DF (December 1980). "Antiarrhythmic effect of the calcium antagonist tiapamil (Ro 11-1781) by intravenous administration in patients with coronary heart disease". Clinical Cardiology. 3 (6): 371–376. doi:10.1002/clc.4960030603. PMID 6161729. S2CID 196402596.
^ "Tiapamil". AdisInsight. Springer Nature Switzerland AG.
^ Cocco G, Chu D, Strozzi C (April 1979). "Dimeditiapramine (Ro 11-1781), a new calcium antagonist, in the management of supraventricular tachyarrhythmias in patients with acute myocardial infarction". Clinical Cardiology. 2 (2): 131–134. doi:10.1002/clc.4960020208. PMID 262567. S2CID 38589956.

[1] Cocco G, Strozzi C, Chu D (June 1979). "Human electropharmacology of the calcium antagonist dimeditiapramine (Ro 11-1781) in coronary patients". Clinical Cardiology. 2 (3): 212–216. doi:10.1002/clc.4960020307. PMID 509799. S2CID 24609271.

[2] Nowak FG, Cocco G, Chu D, Gasser DF (December 1980). "Antiarrhythmic effect of the calcium antagonist tiapamil (Ro 11-1781) by intravenous administration in patients with coronary heart disease". Clinical Cardiology. 3 (6): 371–376. doi:10.1002/clc.4960030603. PMID 6161729. S2CID 196402596.

[3] "Tiapamil". AdisInsight. Springer Nature Switzerland AG.

[4] Cocco G, Chu D, Strozzi C (April 1979). "Dimeditiapramine (Ro 11-1781), a new calcium antagonist, in the management of supraventricular tachyarrhythmias in patients with acute myocardial infarction". Clinical Cardiology. 2 (2): 131–134. doi:10.1002/clc.4960020208. PMID 262567. S2CID 38589956.

[1]

[2]

[3]

[4]

See also

References